Medical device manufacturer Boston Scientific (BSX) disclosed on Wednesday that it is currently suffering from an active cyberattack that is significantly disrupting its operations. The company stated in an SEC filing that the incident has compromised access to critical information systems and applications, specifically hindering its ability to process and ship products. Management emphasized that while they are working diligently to restore affected functions, a specific timeline for full restoration remains unknown. Shares of Boston Scientific fell sharply following the disclosure, dropping 4.5% in morning trading on Wednesday. The stock decline adds to existing pressure on the $72 billion market-cap company, which has already seen its shares nearly halve this year due to a weak profit forecast issued earlier in the first quarter. Analysts at Piper Sandler noted that the inability to ship orders will likely adversely impact sales growth for a business already facing slowing momentum. Matt O'Brien of Piper Sandler, who spoke with company management, estimated that BSX may be able to resume shipping all products in less than three weeks. However, the uncertainty surrounding the duration of the disruption and the potential for extended downtime poses a significant risk to revenue generation. The cyberattack represents a material operational event occurring at a time when the company is already navigating challenges related to sales growth deceleration. Analysts warn that the combination of the ongoing cyber incident and previously weak guidance creates a difficult environment for the stock. The disruption affects core logistics and order processing capabilities, directly threatening short-term revenue realization. Investors are now focused on the speed of recovery and whether the operational halt will result in missed quarterly targets given the current sales slowdown.